China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-A Quality Control on Right Heart Catheterization

What this Trial Is About

This research aims to improve the quality control of right heart catheterization (RHC) procedures across multiple pulmonary hypertension centers in China. It focuses on patients who are undergoing RHC for the first time due to breathlessness or suspected pulmonary hypertension. Historically, limitations in equipment and expertise have restricted RHC use in China, and this study seeks to support better diagnosis and management of pulmonary vascular diseases by collecting detailed data from many centers. The study is observational and does not involve any treatment or intervention. It is conducted at around 30 pulmonary hypertension centers across China, enrolling patients aged 14 years and older who have RHC performed for diagnostic reasons. Researchers will collect baseline data, hemodynamic measurements from RHC, diagnostic classifications, and treatment plans. Patients will continue their routine care and follow-up at their centers while data are gathered according to the study protocol. Participants will be monitored through regular follow-ups, and all collected data will be anonymized and entered into a secure electronic system. The study team will oversee data quality and perform statistical analysis. The main outcome measured is all-cause death within 3 months, with additional assessments including diagnosis type and all-cause death at 1 year. The study started in 2018 and will continue until the end of 2030, tracking patient outcomes over time.

China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization